AstraZeneca tests new biologic in healthy volunteers – no cure expected

NCT ID NCT06103877

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety and tolerability of an experimental drug called AZD1163 in 108 healthy volunteers. Participants received either the drug or a placebo by IV or injection, and researchers monitored side effects and how the drug moved through the body. Since this is a Phase 1 study in healthy people, there is no direct treatment benefit; the results will help decide whether to test the drug in patients with a specific disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD1163 (an experimental biologic drug given by IV or injection)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Show contact details

Locations

Research Site

Glendale, California, 91206, United States
Research Site

Brooklyn, Maryland, 21225, United States
Research Site

Berlin, 14050, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.